3/23
08:04 am
goss
Gossamer Bio (GOSS) had its "neutral" rating reaffirmed by Cantor Fitzgerald.
Medium
Report
Gossamer Bio (GOSS) had its "neutral" rating reaffirmed by Cantor Fitzgerald.
3/20
09:35 pm
goss
Biotech company cuts half its staff after disappointing trial sees stock plummet [Yahoo! Finance]
Medium
Report
Biotech company cuts half its staff after disappointing trial sees stock plummet [Yahoo! Finance]
3/19
10:00 am
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/19
09:00 am
goss
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Medium
Report
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
3/18
09:00 am
goss
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Low
Report
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
3/18
09:00 am
goss
Gossamer Bio, Inc. Investigated by the Portnoy Law Firm
Low
Report
Gossamer Bio, Inc. Investigated by the Portnoy Law Firm
3/17
06:10 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/17
04:42 pm
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/17
04:01 pm
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
3/13
01:47 pm
goss
Gossamer Bio options imply 46.1% move in share price post-earnings [Yahoo! Finance]
Medium
Report
Gossamer Bio options imply 46.1% move in share price post-earnings [Yahoo! Finance]
3/12
10:00 am
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/12
09:00 am
goss
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Medium
Report
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
3/10
04:59 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/9
04:53 am
goss
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations [Yahoo! Finance]
High
Report
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations [Yahoo! Finance]
3/7
06:53 am
goss
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 [Yahoo! Finance]
High
Report
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 [Yahoo! Finance]
3/6
08:03 am
goss
Gossamer Bio (GOSS) had its price target lowered by HC Wainwright from $10.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Gossamer Bio (GOSS) had its price target lowered by HC Wainwright from $10.00 to $5.00. They now have a "buy" rating on the stock.
3/5
05:07 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/5
12:53 pm
goss
Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.
Medium
Report
Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.
3/5
09:00 am
goss
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Medium
Report
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
3/4
06:50 pm
goss
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
Medium
Report
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
3/3
04:08 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/1
04:07 pm
goss
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
2/26
03:18 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
2/26
06:28 am
goss
Gossamer Bio (GOSS) was downgraded by The Goldman Sachs Group, Inc. from "strong-buy" to "hold".
High
Report
Gossamer Bio (GOSS) was downgraded by The Goldman Sachs Group, Inc. from "strong-buy" to "hold".
2/25
06:02 am
goss
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension [Yahoo! Finance]
Medium
Report
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension [Yahoo! Finance]